PMID- 37456173
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 26
IP  - 2
DP  - 2023 Aug
TI  - Safety of non‑peptide thrombopoietin receptor agonists in patients with immune 
      thrombocytopenia: A systematic review and meta‑analysis of short‑term 
      double‑blind randomized clinical trials.
PG  - 393
LID - 10.3892/etm.2023.12092 [doi]
LID - 393
AB  - The aim of the present study was to analyze the safety of non-peptide 
      thrombopoietin receptor agonists (TPO-RAs) for immune thrombocytopenia (ITP) 
      treatment. All studies reporting adverse events (AEs) in relation to ITP 
      treatment with eltrombopag, avatrombopag, and hetrombopag were retrieved from 
      PubMed, Web of Science, and Embase databases. RevMan 5.4.1 was used for 
      meta-analysis, heterogeneity and bias analyses. A total of 1,078 patients from 
      seven eligible studies were enrolled. In the enrolled clinical trials, the 
      double-blind period was between 6 weeks and 6 months. The results revealed that 
      the chances of any AEs [relative risk (RR)=1.16; 95% confidence interval (CI), 
      0.90-1.51; I(2)=78%; P=0.26], grade 3/4 AEs (RR=1.07; 95% CI, 0.63-1.80; I(2)=0%; 
      P=0.81), elevated transaminase levels (RR=1.09; 95% CI, 0.68-1.74; I(2)=0%; 
      P=0.72), thrombosis (RR=1.92; 95% CI, 0.55-6.66; I(2)=0%; P=0.31) and cataracts 
      (RR=0.83; 95% CI, 0.38-1.83; I(2)=0%; P=0.65) were not significantly higher in 
      patients with ITP that received non-peptide TPO-RAs compared with patients with 
      ITP treated with a placebo. The present study indicated that non-peptide TPO-RAs 
      were relatively safe for patients with ITP, at least within 6 months of 
      administration.
CI  - Copyright: (c) Shen et al.
FAU - Shen, Nan
AU  - Shen N
AD  - Department of Pediatrics, Suqian Hospital Affiliated to Xuzhou Medical 
      University, Suqian, Jiangsu 223800, P.R. China.
AD  - Department of Hematology, The Children's Hospital of Soochow University, Suzhou, 
      Jiangsu 215000, P.R. China.
FAU - Qiao, Jibing
AU  - Qiao J
AD  - Department of Pediatrics, Suqian Hospital Affiliated to Xuzhou Medical 
      University, Suqian, Jiangsu 223800, P.R. China.
FAU - Jiang, Yazhou
AU  - Jiang Y
AD  - Department of Pediatrics, Suqian Hospital Affiliated to Xuzhou Medical 
      University, Suqian, Jiangsu 223800, P.R. China.
FAU - Yin, Hanjun
AU  - Yin H
AD  - Department of Pediatrics, Suqian Hospital Affiliated to Xuzhou Medical 
      University, Suqian, Jiangsu 223800, P.R. China.
FAU - Li, Min
AU  - Li M
AD  - Department of Hematology, The Children's Hospital of Soochow University, Suzhou, 
      Jiangsu 215000, P.R. China.
FAU - Zhu, Suyue
AU  - Zhu S
AD  - Department of Pediatrics, Suqian Hospital Affiliated to Xuzhou Medical 
      University, Suqian, Jiangsu 223800, P.R. China.
FAU - Li, Jianqin
AU  - Li J
AD  - Department of Hematology, The Children's Hospital of Soochow University, Suzhou, 
      Jiangsu 215000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20230703
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC10347292
OTO - NOTNLM
OT  - avatrombopag
OT  - eltrombopag
OT  - hetrombopag
OT  - immune thrombocytopenia
OT  - thrombopoietin receptor agonists
COIS- The authors declare that they have no competing interests.
EDAT- 2023/07/17 06:42
MHDA- 2023/07/17 06:43
PMCR- 2023/07/03
CRDT- 2023/07/17 04:21
PHST- 2023/02/22 00:00 [received]
PHST- 2023/06/16 00:00 [accepted]
PHST- 2023/07/17 06:43 [medline]
PHST- 2023/07/17 06:42 [pubmed]
PHST- 2023/07/17 04:21 [entrez]
PHST- 2023/07/03 00:00 [pmc-release]
AID - ETM-26-2-12092 [pii]
AID - 10.3892/etm.2023.12092 [doi]
PST - epublish
SO  - Exp Ther Med. 2023 Jul 3;26(2):393. doi: 10.3892/etm.2023.12092. eCollection 2023 
      Aug.